Showing 8251-8260 of 9758 results for "".
- Mayo Clinic Doctors Receive Stand Up to Cancer Catalyst Award for Melanoma Researchhttps://practicaldermatology.com/news/mayo-clinic-doctors-receive-stand-up-to-cancer-catalyst-award-for-melanoma-research/2457617/Mayo Clinic immunologist and medical oncologist Matthew Block, M.D., Ph.D. and surgeon Tina Hieken, M.D., received a
- Mind the Gap: Disparity Between Urban and Rural Derms Widenshttps://practicaldermatology.com/news/mind-the-gap-disparity-between-urban-and-rural-derms-widens/2457618/The gap between dermatologists in urban and rural areas is widening across the United States, according to a new study of county-level data from 1995 to 2013 in JAMA Dermatology. Specifically, derm
- Latest on Compounding: FDA Proposes to Strike Three Bulk Drug Substances from Listhttps://practicaldermatology.com/news/latest-on-compounding-fda-proposes-to-strike-three-bulk-drug-substances-from-list/2457632/The FDA has issued a
- Novel Epigenetic Mechanism May Cause Drug Resistance in Melanomahttps://practicaldermatology.com/news/novel-epigenetic-mechanism-may-cause-drug-resistance-in-melanoma/2457634/New research sheds light on epigenetic reason for drug resistance in melanoma, and identifies potential therapies that may prevent such resistance, according to a paper in Nature Communications. Mount Sinai researchers identified a novel e
- MC2 Therapeutics Reports Positive Topline Data for Investigational Topical for Psoriasishttps://practicaldermatology.com/news/mc2-therapeutics-reports-positive-topline-data-for-investigational-topical-for-psoriasis/2457641/MC2-01 Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) from MC2 Therapeutics A/S achieved its primary and secondary endpoints, according to recently reported top-line data from the US Phase 3 study. Results of the
- Report: Psoriasis in America in 2018https://practicaldermatology.com/news/report-psoriasis-in-america-in-2018/2457640/Recently released psoriasis survey results reveal that only 10 percent of patients feel their condition is under control with their current treatment plans; meanwhile, their symptoms—and the mental emotional effects of those symptoms—are overwhelming. The survey, "
- "Phenomenal Gains" in Derm Device Market, Global Market Insights Predictshttps://practicaldermatology.com/news/phenomenal-gains-in-derm-device-market-global-market-insights-predicts/2457645/Dermatology devices market, an integral vertical of medical equipment space, of late, has been providing lucrative opportunities to the investors to exploit economies of scale. The claim is very well validated from the increasing attempts by the market giants to brainstorm innovative products tha
- Burt's Bees Nature-Based Sensitive Skin Care Outperforms MD-Recommended Regimenhttps://practicaldermatology.com/news/burts-bees-nature-based-sensitive-skin-care-outperforms-md-recommended-regimen/2457650/Burt’s Bees nature-based sensitive skin regimen is well-tolerated as well as clinically and statistically superior to a leading dermatologist-recommended synthetic regimen, according to a
- Escalier Biosciences' Doses First PsO Patient with ESR-114; Announces Clinical Advisory Boardhttps://practicaldermatology.com/news/escalier-biosciences-doses-first-patient-with-esr-114-announces-clinical-advisory-board/2457652/The first patient has been dosed in a Phase 1/2a study evaluating Escalier Biosciences’ ESR-114 topical gel for mild-to-moderate psoriasis. "The initiation of this study represents a significant milestone for Escalier as it validates o
- Castle Creek Pharmaceuticals Gets FDA Fast Track Designation for Diacerein 1% Ointment for EBShttps://practicaldermatology.com/news/castle-creek-pharmaceuticals-gets-fda-fast-track-designation-for-diacerein-1-ointment-for-ebs/2457655/The U.S. Food & Drug Administration (FDA) granted fast track status to Castle Creek Pharmaceuticals, LLC’s diacerein 1%, ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS). "Fast Track designation is an